CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-11 | BRANDICOURT OLIVIER Director | Grant or award | +18,980 | 46,306 | ||
| 2026-06-11 | Sharp Shalini Director | Grant or award | +18,980 | 38,116 | ||
| 2026-06-11 | HOOPER ANTHONY C Director | Grant or award | +18,980 | 83,720 | ||
| 2026-06-11 | BAKER BROS. ADVISORS LP Director | Grant or award | +18,980 | 161,546 | ||
| 2026-06-11 | BAKER BROS. ADVISORS LP Director | Grant or award | +18,980 | 161,550 | ||
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Grant or award | +177,931 | 5,697,649 | ||
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Sale | −741 | $256.23 | $190K | 1,208 |
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Sale | −859 | $257.59 | $221K | 349 |
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Sale | −200 | $258.28 | $52K | 149 |
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Sale | −149 | $258.81 | $39K | 0 |
| 2026-06-11 | OYLER JOHN Chief Executive Officer | Grant or award · Share Option (Right to Buy) | +344,669 | 344,669 | ||
| 2026-06-08 | Lee Chan Henry SVP, General Counsel | Sale | −711 | $270.24 | $192K | 160 |
| 2026-06-08 | Lee Chan Henry SVP, General Counsel | Sale | −160 | $271.26 | $43K | 0 |
| 2026-06-08 | Wang Lai President, Global Head of R&D | Sale | −1,327 | $269.34 | $357K | 40 |
| 2026-06-08 | Wang Lai President, Global Head of R&D | Sale | −40 | $270.73 | $11K | 0 |
| 2026-06-08 | Wu Xiaobin President and COO | Sale | −1,444 | $269.33 | $389K | 40 |
| 2026-06-08 | Wu Xiaobin President and COO | Sale | −40 | $270.55 | $11K | 0 |
| 2026-06-08 | Ball Titus B. Principal Accounting Officer | Sale | −100 | $271.06 | $27K | 36 |
| 2026-06-08 | Ball Titus B. Principal Accounting Officer | Sale | −36 | $272.08 | $10K | 0 |
| 2026-06-08 | OYLER JOHN Chief Executive Officer | Sale | −3,820 | $270.38 | $1.0M | 1,120 |
Page 12 of 71 · 1,406 trades